New Holdings Doubles Outs of Betting on ES AS Beginning Prevention
A. Novo Holdings Ended with 2024 a Net profit of 60 billion Danish crowns is equivalent to 8 billion euros (US $ 8.66 billion)Mainly driven by the verification of its investment portfolio and the performance of subsidiaries Novo Nordisk E. Novonesis.
Beyond record profitability, it has reached 19.2% in 2024, compared to 9.4% recorded in the previous yearThe headlines of DKK 34 billion (4.6 billion euros) in this field Life SciencesIt made DKK gains 24 billion (3.2 billion euros).
Investments Capital Division also showed growth: It went from DKK 7.6 billion in 2023 DKK 13 billion (1.7 billion euros in the last year).
The positive outcome is slightly reduced to the quantity of the total amount of assets, which fell from 149 billion to 142 billion euros, a direct reflection of the value of Novo Nordisk in the economic market.
Pharma is a worldwide popularity of Drug Shadha against OB WegoviIts market value has fallen by July 2024 amidst the rising competition of American Eli Lily.
Vegovi, Catalyt and Strategy for 2030
Part of the Holding Performance comes from dividends and represents the actions promoted by New Nordisk, as well as earning the CE Shadial sector in 2024: Cottalent purchases for $ 16.5 billion.
The transaction is strategic to expand Vegovi’s production capacity, selling three catalytic plants for $ 11 billion to the new Nordisk.
New Holdings controlls 77% of Novo Nardisk voting shares and is concentrated on fields such as cancer, ES burden and neurodegenerative diseases. Through 2024, 43 new companies have been added to the portfolio and 27 investments have ended.
The headquarters in Denmark and 205 employees and the company worldwide are expanding. One of the current view is to strengthen the presence in Asia. After a series of investments in the Indian market, a new office, which is part of a strategic plan that is aimed at maintaining targets by 2030 – is a priority for health innovation and green transformation.
